Carregant...
P15.18 NAUSEA AND EMESIS DURING NEUROONCOLOGICAL CHEMOTHERAPY - PROBLEM RESOLVED WITH ANY SETRONE?
BACKGROUND: Temozolomide, the most important chemotherapeutic agent used in neurooncology, has moderate emetogenic potential. With the introduction of ondansetron, the first 5HT3-antagonist on the market, most of us neurooncologists thought that the problem of nausea and emesis was resolved. Some pa...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4185657/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.297 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|